Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
The main purpose of this study is to test the safety, tolerable side effects, and determine the highest tolerable dose of the combination of Regorafenib and Nivolumab. Researchers want to find out if this combination of Regorafenib and Nivolumab can help people with metastatic colorectal cancer with mismatch repair (MMR) proficiency.
Colorectal Cancer|Metastatic Colorectal Cancer|Colon Cancer
DRUG: Regorafenib|DRUG: Nivolumab
Maximum Tolerated Dose, To determine the maximum tolerated dose of Regorafenib in combination with Nivolumab in advanced, refractory colorectal cancers., Up to 12 months
Response Rate, To access response rate using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, Every 2nd cycle (Cycles are 28 days) up to 12 months|Overall Survival (OS), Occurrence of Overall Survival, Up to 24 months after conclusion of treatment|Frequency and Severity of Adverse Events, To evaluate the frequency and severity of adverse events and tolerability of the combination regimen., Up to 12 months
The main purpose of this study is to test the safety, tolerable side effects, and determine the highest tolerable dose of the combination of Regorafenib and Nivolumab. Researchers want to find out if this combination of Regorafenib and Nivolumab can help people with metastatic colorectal cancer with mismatch repair (MMR) proficiency.